Fimbrion Therapeutics

Fimbrion Therapeutics is pioneering an antibiotic-sparing approach to combat bacterial infections through its antivirulence platform. The company has established a significant partnership with GSK, which has advanced a UTI candidate into Phase I clinical trials and secured CARB-X funding for its development. With strong academic roots, NIH SBIR grant support, and a focus on high-need areas like recurrent UTIs and tuberculosis, Fimbrion is positioned as an innovator in addressing the global antimicrobial resistance crisis.

Antivirulence platform focusing on small molecule inhibitors of bacterial adhesion and virulence factors (e.g., FimH mannosides for UTIs), designed to treat infections without killing bacteria, thereby sparing the microbiome and reducing selective pressure for antibiotic resistance.

In UTIs, Fimbrion competes with traditional antibiotics, companies developing vaccines (e.g., Sequoia Sciences, Urovant), bacteriophage therapies, and live biotherapeutic products. In tuberculosis, it competes with other biotechs and pharma companies developing novel anti-TB regimens. Its differentiation lies in its first-in-class, microbiome-sparing mechanism of action.